# A Phase 1 Study to Evaluate the Safety and Tolerability of CBL-514 Injection on Convexity or Fullness of Abdominal Subcutaneous Fat in Healthy Volunteers

> **NCT04699669** · PHASE1 · COMPLETED · sponsor: **Caliway Biopharmaceuticals Co., Ltd.** · enrollment: 40 (actual)

## Conditions studied

- Subcutaneous Fat

## Interventions

- **DRUG:** CBL-514, placebo
- **DRUG:** CBL-514, placebo
- **DRUG:** CBL-514

## Key facts

- **NCT ID:** NCT04699669
- **Lead sponsor:** Caliway Biopharmaceuticals Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-11-27
- **Primary completion:** 2019-08-20
- **Final completion:** 2019-08-20
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2021-01-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04699669

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04699669, "A Phase 1 Study to Evaluate the Safety and Tolerability of CBL-514 Injection on Convexity or Fullness of Abdominal Subcutaneous Fat in Healthy Volunteers". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04699669. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*